Vera Therapeutics
VERA
25.45
-1.30
-4.86%
Vera Therapeutics
US · VERA
#2739 by market cap
Listed 2021
25.45
-1.30
-4.86%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $75Market Newswire · 2026/11/13
-
Company notice
Vera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Oliger Christy J.SEC · 2026/5/27
-
Rating change
Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/10/15
-
Company notice
Takeda Pharmaceutical: The U.S. FDA has accepted Rusfertide's New Drug Application and designated it for Priority Review, with the potential to become a first-in-class treatment for polycythemia vera.JPX · 2026/3/2
-
Rating change
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $90Market Newswire · 2026/9/16
-
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $66Market Newswire · 2026/11/6
-
Rating change
BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $60Market Newswire · 2026/10/9
-
BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy RatingMarket Newswire · 2026/11/7
-
Rating change
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $75Market Newswire · 2026/11/6
-
Rating change
Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.Dow Jones · 2026/11/6
-
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/11/6
-
Rating change
Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34Market Newswire · 2026/10/24
-
Rating change
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $76Market Newswire · 2026/10/23
-
Rating change
H.C. Wainwright Remains a Buy on Vera Therapeutics (VERA)TipRanks · 2026/10/1
-
Nebius announced it has begun deploying NVIDIA Vera Rubin systems and expressed optimism regarding the growing demand for high-performance CPUs.Latest · 2026/11/12
-
Rating change
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/10/1
-
Rating change
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $78Market Newswire · 2026/8/31
-
Company notice
Takeda Pharmaceutical: Regarding the U.S. Food and Drug Administration (FDA) approval of MIMRYLO (rusfertide), which has the potential to usher in a paradigm shift in the treatment of polycythemia vera.JPX · 2026/8/29
-
Company notice
Takeda Pharmaceutical: Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia VeraJPX · 2026/8/29
-
Company notice
Takeda Pharmaceutical: Takeda Announces U.S. FDA Accepts NDA and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraJPX · 2026/3/2
-
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/24
-
Rating change
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90Benzinga · 2026/8/12
-
The value per Vera Rubin NVL72 rack has nearly doubled, which is expected to boost Lenovo Group's ISG operating margin by nearly 1 percentage point.Gelonghui Finance · 2026/10/30
-
Rating change
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76Market Newswire · 2026/8/17
-
Rating change
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $100Market Newswire · 2026/8/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Vera Therapeutics discussion 0 comments